A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease

Investigator: Michael Geschwind, MD, PhD

Location(s): United States


The purpose of this study is to assess the efficacy and safety of different doses of laquinimod in Huntington's disease.